Defining a new era of oligonucleotides

Defining a new era of oligonucleotides

We are a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases.

Our chemistry platform enables the creation of highly specific, well characterized oligonucleotides designed to deliver superior efficacy and safety across multiple therapeutic modalities. Our pipeline is initially focused on neurological disorders and extends across several other therapeutic areas.

1st

first to design and bring stereopure and allele-specific medicines to clinic

6

neurology development
programs by end of 2018

3

clinical studies
initiated in 2017

5

nucleic acid modalities being advanced with Wave stereopure chemistry

12+

discovery programs

5

therapeutic areas under active investigation

 

Investor Relations

Recent News

Oct 09, 2018

Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases

Research will focus on inherited retinal diseases associated with RHO, USH2A, ABCA4 and CEP290                Initial development candidate expected in H2 2019 CAMBRIDGE, Mass. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering

Recent News

Oct 09, 2018

Wave Life Sciences to Develop Programs in Rare, Genetic Eye Diseases

Research will focus on inherited retinal diseases associated with RHO, USH2A, ABCA4 and CEP290                Initial development candidate expected in H2 2019 CAMBRIDGE, Mass. , Oct. 09, 2018 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ: WVE), a biotechnology company focused on delivering
Recent News and Events

Copyright West LLC. Minimum 15 minutes delayed.